Browse News
Filter News
Found 806,061 articles
-
To avoid overextending yourself and harming your work-life balance, how should you set and maintain boundaries at work?
-
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
3/28/2024
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the supplemental New Drug Application (“sNDA”) for savolitinib, in adult patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) with mesenchymal epithelial transition factor (“MET”) exon 14 skipping alteration, has been accepted for review by the China National Medical Products Administration (NMPA).
-
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering - March 28, 2024
3/28/2024
Praxis Precision Medicines, Inc. announced the pricing of its underwritten public offering of 3,318,585 shares of its common stock at a public offering price per share of $56.50 and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 221,238 shares of common stock at a purchase price of $56.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant.
-
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
3/28/2024
Stoke Therapeutics, Inc. announced the pricing of its upsized underwritten public offering of 5,555,557 shares of its common stock at a price to the public of $13.50 per share and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 3,703,730 shares of its common stock at a price to the public of $13.4999.
-
Promising First-In-Human Phase 1B Clinical Study Data from VRON-0200, a Novel, First-in-Class Checkpoint Modifier Immunotherapy for Chronic Hepatitis B Virus Functional Cure, Presented as Late-Breaker at 2024 APASL Global Liver Meeting
3/28/2024
Virion Therapeutics, LLC announced promising safety results from the first-ever human data from its novel, first-in-class, checkpoint modifier immunotherapy, VRON-0200, for HBV functional cure, presented by Professor Grace Wong, M.D., from the Chinese University of Hong Kong, as a late breaker oral presentation at the 33rd Annual Meeting of APASL in Kyoto, Japan.
-
Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
3/28/2024
Intravacc and Primrose Bio announced a strategic partnership to enhance the development and supply of conjugate vaccines.
-
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
3/28/2024
Akebia Therapeutics®, Inc. announced that the U.S. Food and Drug Administration has approved Vafseo® Tablets for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months.
-
CLS Americas Announces ROSE Urology will use TRANBERG Laser to Treat Prostate Cancer Patients with Focal Laser Ablation
3/28/2024
Clinical Laserthermia Systems Americas, Inc. announced that ROSE Urology, LLC, located in Vero Beach, Florida, will begin using the TRANBERG™ Thermal Therapy System to treat prostate cancer patients.
-
Erasca Announces $45 Million Oversubscribed Private Placement Financing
3/28/2024
Erasca, Inc. announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 21,844,660 shares of its common stock in an oversubscribed private placement at a price of $2.06 per share.
-
China Medical System (867.HK)2023 Annual Results: Despite of the Temporary Financial Performance Pressure Fresh Catalysts Emerged from Successive Innovation Breakthroughs
3/28/2024
On March 27, 2024, China Medical System released its 2023 annual results. The Company recorded a turnover of RMB8,013 million, a year-on-year decrease of 12.4%; in the case that all medicines were directly sold by the Group, the turnover would be RMB 9,472 million, a year-on-year decrease of 9.8%.
-
Vicore Announces Presentations at the 2024 American Thoracic Society International Conference
3/28/2024
Vicore Pharma Holding AB announced multiple presentations at the 2024 American Thoracic Society International Conference, including an oral late-breaking presentation of the final Phase 2a AIR data of buloxibutid in patients suffering from idiopathic pulmonary fibrosis.
-
Vafseo® approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients
3/28/2024
CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. announced that the U.S. Food and Drug Administration has approved Vafseo tablets for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months.
-
Sequana Medical announces 2023 Full Year Results and 2024 Outlook
3/28/2024
Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces its financial results for the year ended 31 December 2023, and provides a business update and outlook for 2024 and beyond.
-
Inventiva announces the nomination of Andre Turenne as Director
3/28/2024
Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis, also known as non-alcoholic steatohepatitis and other diseases with significant unmet medical needs, announced the nomination of Andre Turenne to its Board of Directors.
-
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
3/28/2024
Medigene AG reported financial results for the fiscal year ended December 31, 2023, and provided a corporate update.
-
2024 Job Search Toolkit
3/28/2024
BioSpace has updated our Job Search Toolkit for spring, including recent resources to help you succeed with your next job search. -
5 Top Companies Hiring in New Jersey
3/28/2024
Looking for a biopharma job in New Jersey? Check out the BioSpace list of five top companies hiring life sciences professionals like you. -
Moderna has entered into a development and commercialization funding agreement with asset management firm Blackstone Life Sciences to help advance its pipeline of flu vaccine candidates.
-
Novocure’s stock spiked more than 15% Wednesday morning after the company announced its Tumor Treating Fields therapy met the primary endpoint in a late-stage trial.
-
While Pfizer has ended one of its two Phase III studies for inclacumab in sickle cell disease, the company is still eyeing an approval for the antibody in the inherited blood disorder by 2026.